Celebrex® Infromative Articles US approval of COX-2 inhibitor
.(News) Lancet v353, n9148 (Jan 16, 1999):220 (1pages). COPYRIGHT 1999 Lancet Ltd. On Jan 1, the US FDA approved Searle's celecoxib (Celebrex), the first cyclooxygenase-2
inhibitor, for osteoarthritis and rheumatoid arthritis. Trials showed that patients on celecoxib had a substantially lower risk of ulcers than when on non-steroidal
anti-inflammatory drugs, but this needs testing in thousands of patients, the FDA said. Users will be advised that the drug poses risks of gastrointestinal ulceration, bleeding, and
perforation. Side-effects include dyspepsia, diarrhoea, and abdominal pain. Contraindications include allergy to aspirin, NSAIDs, or sulphonamides. ORDER CELEBREX® ONLINE NOW! |
